NEUROKINE PHARMACEUTICALS INC. - Statements of Operations (USD $)	12 Months Ended				128 Months Ended
	Jan. 31, 2013		Jan. 31, 2012		Jan. 31, 2013
EXPENSES
Amortization	$ 455		$ 455		$ 948
Consulting fees			126,519		126,519
Foreign exchange loss (gain)	(799)		3,541		8,989
General and administrative	18,341		68,384		221,502
Management fees	30,000	[1]	60,185	[1]	169,161	[1]
Professional fees	40,896		45,386		182,379
Research and development			58,041		282,715
Royalties					500,000
TOTAL EXPENSES	88,893		362,511		1,492,213
Loss from operations	(88,893)		(362,511)		(1,492,213)
Accretion of discounts on convertible debentures	(95,759)		(96,531)		(202,988)
Financing costs			(306,449)		(306,449)
Gain (loss) on change in fair value of derivative	550,419		2,244,910		(72,695)
Interest expense	(24,342)		(61,685)		(86,027)
Total Other Income (Expenses)	430,318		1,780,245		(668,159)
Net Income (loss)	341,425		1,417,734		(2,160,372)
Net income (loss) per share, basic	0.01		0.04
Net income (loss) per share, diluted			$ 0.02
Weighted average shares outstanding, basic	35,767,073		33,939,227
Weighted average shares outstanding, diluted	170,421,291		65,331,413

[1] See Note 10